• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes care >Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals.
【24h】

Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals.

机译：血浆单核细胞趋化蛋白-1浓度与中年糖尿病和非糖尿病个体心血管疾病死亡率之间的关联。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemokine involved into the pathogenesis of atherosclerosis and has prognostic value in the acute and chronic phases in patients with acute coronary syndromes. RESEARCH DESIGN AND METHODS: MCP-1/CCL2 concentration was measured in plasma fractions of 363 middle-aged overweight/obese individuals (aged 61 +/- 12 years, BMI 30.1 +/- 6.6 kg/m(2), 15% with type 2 diabetes, and 12% with impaired glucose tolerance) of a population survey carried out in 1990-1991 in Lombardy, Italy (Cremona Study), and cardiovascular disease (CVD) mortality was assessed in 2006 through Regional Health Registry files. RESULTS: At baseline MCP-1/CCL2 was increased in individuals with type 2 diabetes (P < 0.05) and showed significant correlations with biochemical risk markers of atherosclerosis. After 15 years, among the 363 subjects, there were 82 deaths due to CVD. In univariate analysis age, sex, fasting glucose and insulin, fibrinogen, glucose tolerance status, smoking habit, and MCP-1/CCL2 were associated with CVD mortality. Age, sex, fasting serum glucose, MCP-1/CCL2, and smoking habit maintained an independent association with CVD mortality in multiple regression analysis. In a subgroup of 113 subjects in whom data for C-reactive protein (CRP) were available, its level was not predictive of CVD mortality. CONCLUSIONS: In middle-aged overweight/obese individuals MCP-1/CCL2 was independently associated with CVD mortality. Further studies will be necessary to establish its role as a surrogate biomarker and as a potential therapeutic target.
机译：目的：单核细胞趋化蛋白-1（MCP-1 / CCL2）是一种参与动脉粥样硬化发病机制的趋化因子，在急性冠状动脉综合征的慢性期和慢性期具有预后价值。研究设计与方法：测定了363名中年超重/肥胖个体（61 +/- 12岁，BMI 30.1 +/- 6.6 kg / m（2），其中15％的人）的血浆分数中的MCP-1 / CCL2浓度。 1990年至1991年在意大利伦巴第进行的人群调查（Cremona研究）对2型糖尿病和12％的葡萄糖耐量受损（糖耐量减低）和心血管疾病（CVD）死亡率进行了评估，并于2006年通过“区域健康注册”档案进行了评估。结果：在基线时，患有2型糖尿病的患者的MCP-1 / CCL2升高（P <0.05），并且与动脉粥样硬化的生化危险指标显着相关。 15年后，在363名受试者中，有82名因CVD死亡。在单变量分析中，年龄，性别，空腹血糖和胰岛素，纤维蛋白原，葡萄糖耐量状态，吸烟习惯以及MCP-1 / CCL2与CVD死亡率相关。在多元回归分析中，年龄，性别，空腹血糖，MCP-1 / CCL2和吸烟习惯与CVD死亡率保持独立相关。在可获得C反应蛋白（CRP）数据的113个受试者亚组中，其水平不能预测CVD的死亡率。结论：在中年超重/肥胖个体中，MCP-1 / CCL2与CVD死亡率独立相关。为了确定其作为替代生物标志物和潜在治疗靶标的作用，有必要进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号